Wells Fargo raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $74 and keeps an Overweight rating on the shares after sephience was approved by FDA as expected and with no surprises on label. The firm notes that label came in line with its expectations, very similar to Kuvan, with pricing higher than Street expectation. Wells thinks there is upside to current sell-side peak estimates even with modest assumptions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Positive Outlook for PTC Therapeutics: Buy Rating Affirmed Following Sephience Approval and Strategic Launch
- PTC Therapeutics price target raised to $80 from $71 at UBS
- Positive Outlook for PTC Therapeutics’ Sephience: Strong Market Potential and Revenue Prospects
- PTC Therapeutics price target raised to $46 from $42 at Barclays
- PTC Therapeutics Gains FDA Approval for Sephience